Greenleaf Trust Genmab A/S Transaction History

Greenleaf Trust

  • $11.2 Billion
  • Q3 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 22, 2024
BUY
$25.13 - $30.27 $332,469 - $400,472
13,230 New
13,230 $332,000
Q3 2023

Nov 09, 2023
SELL
$35.27 - $42.24 $11,356 - $13,601
-322 Reduced 5.08%
6,018 $212,000
Q2 2023

Aug 09, 2023
SELL
$37.4 - $42.94 $374 - $429
-10 Reduced 0.16%
6,340 $240,000
Q1 2023

May 11, 2023
BUY
$34.88 - $43.22 $10,115 - $12,533
290 Added 4.79%
6,350 $239,000
Q4 2022

Jan 25, 2023
BUY
$33.8 - $47.06 $204,827 - $285,183
6,060 New
6,060 $257,000
Q2 2022

Aug 12, 2022
SELL
$26.83 - $38.57 $63,855 - $91,796
-2,380 Reduced 25.43%
6,980 $227,000
Q1 2022

Apr 27, 2022
SELL
$30.95 - $39.68 $21,355 - $27,379
-690 Reduced 6.87%
9,360 $339,000
Q4 2021

Feb 11, 2022
SELL
$35.87 - $47.12 $3,586 - $4,712
-100 Reduced 0.99%
10,050 $398,000
Q3 2021

Nov 12, 2021
BUY
$41.55 - $48.72 $9,972 - $11,692
240 Added 2.42%
10,150 $444,000
Q2 2021

Aug 10, 2021
BUY
$32.88 - $44.57 $10,192 - $13,816
310 Added 3.23%
9,910 $405,000
Q1 2021

Apr 30, 2021
BUY
$30.92 - $44.4 $79,155 - $113,664
2,560 Added 36.36%
9,600 $315,000
Q4 2020

Feb 08, 2021
BUY
$33.66 - $40.76 $4,712 - $5,706
140 Added 2.03%
7,040 $286,000
Q3 2020

Oct 30, 2020
BUY
$33.07 - $38.68 $5,621 - $6,575
170 Added 2.53%
6,900 $253,000
Q2 2020

Aug 12, 2020
BUY
$20.05 - $33.89 $134,936 - $228,079
6,730 New
6,730 $228,000

Others Institutions Holding GMAB

# of Institutions
236
Shares Held
52.5M
Call Options Held
10.2K
Put Options Held
25.5K
View Full List

About GENMAB A/S

GMAB Quotes by TradingView
  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Greenleaf Trust Portfolio

Follow Greenleaf Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenleaf Trust, based on Form 13F filings with the SEC.

News

Stay updated on Greenleaf Trust with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email